Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2014, Vol. 19 ›› Issue (9): 1075-1080.
SHANG Li-na, HONG Ming-yue
Received:
2013-08-30
Revised:
2014-04-08
Online:
2014-09-26
Published:
2014-09-26
CLC Number:
SHANG Li-na, HONG Ming-yue. Recent progresses on antibody-targeted conjugates of antitumor antibiotics[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1075-1080.
Add to citation manager EndNote|Ris|BibTeX
URL: https://manu41.magtech.com.cn/Jweb_clyl/EN/
https://manu41.magtech.com.cn/Jweb_clyl/EN/Y2014/V19/I9/1075
[1] | Verdoodt B, Vogt M, Schmitz I, et al.Salinomycin induces autophagy in colon and breastcancer cells with concomitant generation of reactive oxygen species[J].PLo S One,2012,7(9): e44132. |
[2] | Li W, Khullar A, Chou S, et al.Biosynthesis of Sibiromycin, a Potent Antitumor Antibiotic[J]. Appl Environ Microbiol,2009,75(9):2869-2878. |
[3] | Flygare JA, Pillow TH, Aristoff P.Antibody-drug conjugates for the treatment of cancer[J]. Chemical Biology & Drug Design,2013,81(1):113-121. |
[4] | 钱璟. 烯二炔类抗肿瘤抗生素的研究进展[J].中国现代药物应用,2012,6(22):124-125. |
[5] | Feng Y, Shao RG, Dai Y, et al.Comparison of the antitumor activities of immuneconjugates composed of lidamycin and monoclonal antibody fab' fragment with different linkers[J].Yao Xue Xue Bao,2010,45(5):571-575. |
[6] | Fang H, Miao Q.Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin[J].Sci China Life Sci,2011,54(3):255-262. |
[7] | Zhong GS, Wu MN, Guo XF, et al.Small antibody fusion proteins with complementarity -determining regions and lidamycin for tumor targeting therapy[J].Oncol Lett,2013,5(4): 1183-1188. |
[8] | 高瑞娟,李亮,赵春燕,等.单链抗体与力达霉素基因工程强化融合蛋白Fv-LDP-AE 的抗肿瘤作用[J].中国药学杂志,2010,58(11):808-813. |
[9] | Zhang Q, Liu XJ, Hu L, et al.Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy[J].Int J Mol Med,2012,29(3): 409-415. |
[10] | Zhang Q, Liu XJ, Li C, et al.Tissue factor-targeted lidamycin inhibits growth and metastasis of colon carcinoma[J].Oncol Lett,2013,6(3): 801-806. |
[11] | 郭晓芳,来小飞,钟根深,等.以人表皮生长因子受体 2 为靶点的强化融合蛋白 LDP-Hr-AE 的构建及抗肿瘤活性研究[J].中国药学杂志,2012,47(12):941-947. |
[12] | Ricart AD.Antibody-drug conjugates of calicheamicin derivative: gemtuzumabozogamicin and inotuzumabozogamicin[J].Clin Cancer Res,2011,17(20): 6417-6427. |
[13] | de Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumabozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells[J].Leukemia,2012,26(2):255-264. |
[14] | DiJoseph JF, Dougher MM, Evans DY, et al. Preclinical anti-tumor activity of antibody-targetedchemotherapy with CMC-544 (inotuzumabozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemo- therapy with CVP or CHOP[J].Cancer Chemother Pharmacol,2011,67(4):741-749. |
[15] | Ogura M, Hatake K, Ando K, et al.Phase I study of anti-CD22 immunoconjugate inotuzumabozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma[J].Cancer Sci,2012,103(5): 933-938. |
[16] | Shao RG.Pharmacology and therapeutic applications of enediyne antitumor antibiotics[J]. Curr Mol Pharmacol,2008,1(1): 50-60. |
[17] | Bernt KM, Prokop A, Huebener N, et al.Eradication of CD19+ leukemia by targeted calicheamicin theta[J].Bioconjug Chem,2009,20(8): 1587-1594. |
[18] | Nagamitsu A, Greish K, Maeda H.Elevating Blood Pressure as a Strategy to Increase Tumor-targeted Delivery of Macromolecular Drug SMANCS: Cases of Advanced Solid Tumors[J].Jpn J Clin Oncol,2009,39(11):756-766. |
[19] | YataY, Otsuji E, Okamoto K, et al. Decreased production of anti-mouse antibody after administration of human/mouse chimeric monoclonal antibody-neocarzinostatin conjugate to human[J].Hepatogastroenterology,2003,50(49):80-84. |
[20] | Jin W, Trzupek JD, Rayl TJ, et al.A unique class of duocarmycin and CC-1065 analogues subject to reductive activation[J]. J Am Chem Soc,2007,129(49):15391-15397. |
[21] | Wang Y, Jiang J, Jiang XJ, et al.Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog[J].Bioorg Med Chem,2008,16(13): 6552-6559. |
[22] | Suzawa T, Nagamura S, Saito H, et al.Synthesis of a novel duocarmycin derivative DU-257 and its application to immunoconjugate using poly(ethylene glycol)-dipeptidyl linker capable of tumor specific activation[J].Bioorg Med Chem,2000,8(8): 2175-2184. |
[23] | Lillo AM, Sun C, Gao C, et al.A human single-chain antibody specific for integrin alpha3beta1 capable of cell internalization and delivery of antitumor agents[J].Chem Biol,2004,11(7):897-906. |
[24] | Sivam GP, Martin PJ, Peisfeld RA, et al.Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma[J]. Cancer Res,1995,55(11):2352-2356. |
[25] | Willner D, Trail PA, Hofstead SJ, et al.(6-Maleimidocaproyl) hydrazone of doxorubicin- a new derivative for the preparation of immunoconjugates of doxorubicin[J]. Bioconjug Chem,1993,4(6):521-527. |
[26] | Tan L, Neoh KG, Kang ET, et al.PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells[J].Macromol Biosci,2011,11(10): 1331-1335. |
[27] | Schmid B, Chung DE, Warnecke A, et al.Albumin-binding prodrugs of camptothecin and doxorubicin with an ala-leu-ala-leu-linker that are cleaved by cathepsin B: Synthesis and antitumor efficacy[J].Bioconjug Chem,2007,18(3):702-716. |
[28] | Jeffrey SC, Nguyen MT, Andreyka JB, et al.Dipeptide-based highly potent doxorubicin antibody conjugates[J].Bioorg Med Chem Lett,2006,16(2):358-362. |
[29] | Han LA, Huang RQ, Li JF, et al.Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoaminedendrimer[J]. Biomaterials,2011,32(4): 1242-1252. |
[30] | Hu ZL, Jiang XJ, Albright CF, et al.Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents[J].Bioorg Med Chem Lett,2010,20(3): 853-856. |
[31] | 杨鸣琦,张福良,路宏朝.抗肿瘤抗生素研究进展[J].西北农林科技大学学报,2005,23(12):27-32. |
[32] | 戴垚,刘秀均,甄永苏.抗 IV 型胶原酶单抗与平阳霉素新型免疫偶联物的抗肿瘤作用[J].药学学报,2006,41(1):41-46. |
[33] | Chen WZ, Zhang Y, Liang CS, et al.Effect of antibody-targeted chemotherapy with pingyangmycin on prostate cancer cells in vitro[J].Nan Fang Yi Ke Da Xue Xue Bao,2008, 28(3):406-408. |
[34] | L ZhD.Preparation of conjugate of chemotactic peptide fMLP-boanmycin and initial evaluation of its antitumor activity in vivo[J].China Pharmacist,2010,1:012. |
[1] | LIU Yujia, LI Li, HU Xiaoping, ZHONG Like, LI Jingjing, HUANG Ping, ZHANG Yiwen. A correlation analysis between survival rate and the characteristic gene of gastric cancer based on bioinformatics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 852-859. |
[2] | YUAN Lijialong, QIN Xuping. ATP synthase beta subunit function and disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 464-470. |
[3] | LI Meng-qiu, DOU Jie, DU Wei, LI Xin-ya, LIN Jian, ZHOU Chang-lin. Effects of tripterine on the immunosuppression action and expression of IL-6 mRNA in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(2): 158-163. |
[4] | WEN Zhi-zhen, YU Bao-hai, SU Hai-xiang, WEI Hu-lai, HAO Chun-yan. Changes of Bcl-2 expression in apoptosis induced by resveratrol in K562 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(4): 421-423. |
[5] | XIA Hui, YU Chang-hai, YU Jian-qi, LI Jie, ZHANG Bao-shi, LI Ying-jie. Effect of IFN-γ on A549 cell proliferation and expression of P21 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(4): 424-426. |
[6] | WANG Zhi-peng, ZHANG Rong, LIU Li, MEI Qi-bing. Protection of Mn2+on Injury of human kidney tubularepithelial cell line induced by bentamicin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(12): 1364-1367. |
[7] | LIU Huan-Long, FENG Xiao-Long, WANG Xin-Yu. Effects of 1-menthol and azone on percutaneous penetration of bifonazole in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(11): 1253-1255. |
[8] | ZHANG Yu. Progress in the research of P-gp inhibitors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(10): 1087-1090. |
[9] | WEN Jun, Zhang Yi Wei, Nie Ya-Li, XU Ming. Inhibition of p42/44 MAPK kinase enhances diallyl disulfide induced apoptosis in human CNE2 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(9): 983-987. |
[10] | YU Juan, NI Xiu-Shi, XU Yun. Phytoestrogens and progress of protective effects researching on central nerve system [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(8): 851-854. |
[11] | ZHENG Min, HE Min, XU Ji-Liang, YIN Xiao-Qin. Expression of type Ⅰ transforming growth factor β receptor in renal cortex of streptozotocin-induced type Ⅱ diabetic rats and the regulation of valsartan [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(8): 945-948. |
[12] | DENG Li-Juan, LI Zhan-Jun, LE Jia-Jing, YAN An-Zhuang, XUN Kang-Sen. Effects of seal oil on the correlation between hepatocyte cytochrome P450 2E1 expression and oxidation, antioxidation in rats with nonalcoholic fatty liver [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(7): 755-758. |
[13] | SUN Yan-Hui, HOU Xiang-Lin, LI Xing-Yu. Study on GM-CSF expression in mouse brain tissue induced by agaricus blazei polysaccharide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(7): 799-802. |
[14] | ZHAN Xiao-Yun, REN Yu-Hong, ZHANG Qiang, LU Yan-Hua, WEI Dong-Zhi, LIU Jian-Wen. A novel antisense oligodeoxynucleotide-doxorubicin conjugate against the multidrug resistance gene mdr1:inhibition to KB-A-1 cell and P-glycoprotein expression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(4): 403-410. |
[15] | TANG Yong-Bo, WANG Qian-Lei, ZHU Bing-Yang, HUANG Hong-Lin, LIAO Duan-Fang. Study of 17 β-Estradiol supplementation on increasing eNOS expression and NO production in ovariectomized rat heart [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(4): 411-416. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||